Personalized cancer vaccine plus pembrolizumab for kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a personalized vaccine made from your tumor's unique mutations, given with the immunotherapy drug pembrolizumab, for people with advanced kidney cancer that has stopped responding to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III or IV kidney cancer that has spread or come back and can't be removed with surgery.
- Your disease has been stable for at least 3 months while on pembrolizumab, but then it started growing or you couldn't tolerate the side effects.
- You have at least one tumor that can be measured on a scan (like a CT or MRI).
- You are 18 years or older, and your doctor expects you to live at least 3 more months.
- You have enough tumor tissue from a past biopsy or surgery to run special genetic tests.
- Your blood counts, liver, kidney, and heart function are within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three medicines—pembrolizumab (a drug that helps your immune system fight cancer), belzutifan, and lenvatinib (drugs that slow tumor growth)—in patients with early-stage kidney cancer who are candidates for surgery. The goal is to see if this combination can improve outcomes before or alongside surgery.
This trial tests whether personalized monitoring of cancer DNA in your blood (MRD) can guide treatment decisions after kidney cancer surgery. If MRD is detected, you may receive extra immunotherapy to reduce the risk of cancer returning.
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
This Phase 2 study tests a personalized kidney cancer vaccine made from your own immune cells. It aims to help your immune system recognize and attack clear cell kidney cancer after surgery, potentially lowering the chance of the cancer coming back.
This early-phase trial tests a personalized cancer vaccine made from your tumor, along with pembrolizumab, to help the immune system attack advanced pancreatic cancer. It may be an option if your cancer has specific immune “targets” and if you meet several health, lab, and infection requirements.
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.